The CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques) trial was a prospective, multicentre, open-label, phase 3 trial that randomly assigned patients with Memorial Sloan Kettering Cancer Center (MSKCC) intermediate or poor risk metastatic renal cell carcinoma (mRCC) to undergo cytoreductive nephrectomy (CNx) followed by sunitinib or to sunitinib alone without nephrectomy. The study was designed to test the non-inferiority of sunitinib alone with respect to the primary endpoint overall survival. Secondary endpoints included progression-free survival, objective response rate (percentage of patients with complete or partial response), clinical benefit (percentage of patients with complete or partial response or stable disease for more than 12 weeks), CNx in the sunitinib-alone group, postoperative morbidity and mortality, and safety.
Urology. 2018 Aug 02 [Epub ahead of print]
Claudia Kesch, Peter C Black
Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada., Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: .